Using a randomized "double-blind" "placebo-controlled" design, 16 experienced male bodybuilders (age: 19-44 yr) either received ND (200 (-1), intramuscularly) or placebo for 8 wk. Body composition was assessed using the four-component model, combining results from underwater weighing, dual-energy x-ray absorptiometry (DXA), and deuterium dilution. Total bone mineral content and density were measured using DXA. Water compartments (extracellular water [ECW] and intracellular water [ICW]) were determined using deuterium dilution and bromide dilution.
Because the ultimate goal of a steroid cycle is to increase strength and muscle size, the associated spike in estrogen which accompanies steroids such as Testosterone is considered undesirable. In order to disassociate the two effects, two classes of drug are used. Medications such as Nolvadex or Clomid target the estrogen receptors. They make it more difficult for the estrogen to exert it’s influence within the body thus allowing the testosterone to act more freely. The second class is aromatase inhibitors such as Femara. They target the aromatase enzyme itself in order to prevent the production of estrogen in the first place. Sometimes, it’s not always clear which option you should go with or even what the differences are between the two. Lets clear that up a little.